Результаты поиска

Combined spatial metabolomics and 4D-DIA quantitative proteomics approaches to explore the relationship between lung cancer and the heart.

Lung cancer and cardiovascular disease pose persistent threats to human health, despite advancements in targeted therapy, percutaneous coronary intervention, and drug treatments. Challenges such as side effects, drug resistance, hospitalization rates, and mortality remain high. These diseases are closely linked, sharing common risk factors and intricately influencing each other. This study aims to investigate the interplay between lung disease and cardiovascular disease by examining changes in cardiac metabolites and protein expression using spatial metabolomics and 4D-DIA quantitative proteom

A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.

Multiple myeloma (MM), the second most common haematological malignancy, is currently incurable because patients often develop multiple drug resistance and experience subsequent relapse of the disease. This study aims to identify a potential therapeutic agent that can counter bortezomib (BTZ) resistance in MM. DCZ0358, a novel alkaloid compound, is found to exert potent cytotoxic effects against BTZ-resistant MM cells in vivo and in vitro. The anti-myeloma activity of DCZ0358 is associated with inhibition of cell proliferation, promotion of cell apoptosis via caspase-mediated apoptotic pathway

Осуществимость консолидации после вводного курса с клеточной терапией BCMA CAR-T в недавно диагностированном миеломе, не поступающей в ASCT: предварительная серия дел.

Антигенная химериковая антигенная терапия (CAR) T клеточная терапия B-клеток (BCMA) продемонстрировала многообещающую эффективность при повторном/изобилии множественной миеломы (MM). Однако доказательства, подтверждающие его использование в более ранних лечебных условиях, по-прежнему ограничены. В настоящем исследовании представлена предварительная серия дел, в которой оценивается практическая возможность применения клеточной терапии BCMA CAR-T в качестве клеточной терапии в период после ввода у недавно диагностированных пациентов с несколькими миеломой (NDMM), которые не перешли к автоматичес

Risk and Response-Adapted Treatment in Multiple Myeloma.

Myeloma therapeutic strategies have been adapted to patients' age and comorbidities for a long time. However, although cytogenetics and clinical presentations (plasmablastic cytology; extramedullary disease) are major prognostic factors, until recently, all patients received the same treatment whatever their initial risk. No strong evidence allows us to use a personalized treatment according to one cytogenetic abnormality in newly diagnosed myeloma. Retrospective studies showed a benefit of a double autologous transplant in high-risk cytogenetics according to the International Myeloma Working

Сердечно-сосудистые заболевания

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Изменяющиеся методы лечения и результаты у пациентов с недавно диагностированными множественными миэломами, которые проходят автологическую трансплантацию стволовых клеток: исследование реального мира в Китае.

Это одноцентровое ретроспективное исследование было направлено на оценку тенденций в области клинических характеристик, методов лечения и результатов лечения пациентов с недавно диагностированными множественными миеломами (НДММ), которые прошли первоначальную аутологическую трансплантацию стволовых клеток (ASCT) в период между 2007 и 2023 в Китае. МЕТОДЫ: Всего 390 пациенты с NDMM были сгруппированы в three Временные группы: 2007–2012 (В тыс.79 - пациенты), 2013–2018 (В тыс.143 пациентов), и 2019–2023 (В тыс.168 - пациенты). За эти периоды были проанализированы клинические характеристики, мето

Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools.

Thromboembolism in multiple myeloma (MM) patients remains a common complication that renders the optimization of our thromboprophylaxis practice necessary. This review aims to make clear the need for the development of more accurate risk assessment tools and means of thrombosis prevention. Current clinical practice is guided by available guidelines published by the IMWG in 2014, but the extent to which these are implemented is unclear. Recently, several groups developed clinical scores for thrombosis risk in MM in an attempt to improve risk stratification, but these have not been validated or

Characteristics and outcomes of patients with lymphoma who developed therapy-related acute myeloid leukemia or myelodysplastic syndrome - a retrospective analysis of the Polish Adult Leukemia Group.

IntroductionEnhancing lymphoma outcomes increases the risk of therapy-related neoplasms such as acute myeloid leukemia (t-AML) and myelodysplastic syndrome (t-MDS).Material and methodsOur study, conducted at seven Polish hematology centers between 2011 and 2018, explores clinical features, outcomes, and prognostic factors of t-AML and t-MDS arising after initial lymphoid neoplasms.ResultsThe analysis included 57 patients of median age 65 with t-MDS (n = 38) and t-AML (n = 19). The median time to the onset of t-MDS/AML was 58.7 months. The median overall survival (OS) was 16.1 months. The prese

Development of novel gene signatures for the risk stratification of prognosis and diagnostic prediction of osteosarcoma patients using bioinformatics analysis.

BackgroundOsteosarcoma (OS) is a common malignant bone cancer in children and teenagers that originates from osteoblast cells. Although many biomarkers have been reported in OS, they have not improved the prognosis of this disease. This study sought to identify effective biomarkers for the early diagnosis and prognosis of OS using a comprehensive bioinformatics analysis.MethodsOS-associated microRNAs (miRNAs) were screened in the Human microRNA Disease Database (HMDD). The differentially expressed genes (DEGs) related to OS were screened using 3 data sets (GSE16088, GSE36001, and GSE56001) fro

Proteasome Inhibitors for the Treatment of Multiple Myeloma.

Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment over the past decade. Many PIs are being developed and evaluated in the preclinical and clinical setting. The first-in-class PI, bortezomib, was approved by the US food and drug administration in 2003. Carfilzomib is a next-generation PI, which selectively and irreversibly inhibits proteasome enzymatic activities in a dose-dependent manner. Ixazomib was the first oral PI to be developed and has a robust efficacy and favorable safety profile in patients with multiple myeloma. These PIs, together with other

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.

Survival of myeloma patients has greatly improved with the use of autologous stem cell transplantation and novel agents, such as proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. Compared to bortezomib- and lenalidomide-based regimens alone, the addition of high-dose melphalan followed by autologous transplantation significantly improves progression-free survival, although an overall survival benefit was not observed in all trials. Moreover, follow up of recent trials is still too short to show any difference in survival. In the light of these findings, novel agent-based

Лечение чернокожих и белых пожилых людей с множественной миеломой: анализ SEER-Medicare.

Цель настоящего исследования заключается в том, чтобы описать время начала лечения чернокожих и белых пожилых людей с множественными миеломой (ММ) и проверить гипотезу о том, что различия между чернокожими и белыми в начале лечения с течением времени возросли.65+) диагноз миэломы 2007-2017 были выявлены в базе данных SEER-Medicare. Непрерывное медицинское обслуживание 12 за месяцы до и после диагностики или до смерти, а также по части D 12 - месяцев после диагностики или до смерти. Мы изучали время начала лечения по расовому признаку three период диагностирования2007-10, 2011-2014, 2015-2017)

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.

BackgroundMyeloma causes profound immunodeficiency and recurrent, serious infections. Around 5500 new cases of myeloma are diagnosed per year in the UK, and a quarter of patients will have a serious infection within 3 months of diagnosis. We aimed to assess whether patients newly diagnosed with myeloma benefit from antibiotic prophylaxis to prevent infection, and to investigate the effect on antibiotic-resistant organism carriage and health care-associated infections in patients with newly diagnosed myeloma.MethodsTEAMM was a prospective, multicentre, double-blind, placebo-controlled randomise

Сосуществование Лактиплантацилла и Виккерхамомиц в верхнем слое сахарного тростника стимулирует потенциальное подавление патогенов и аэробную стабильность за счет увеличения производства лактической кислоты и уксусной кислоты.

Чтобы определить сосуществующие бактерии и дрожжи в верхнем слое сахарного тростника, которые определяют качество ферментации и повышают безопасность корма, мы манипулировали эпифитической микробиотой сверху сахарного тростника путем селективного подавления дрожжей (АФ) или бактерий с лактической кислотой (АБ) перед повторной цензурой, используя в качестве контроля неочищенные (КК) и стерилизованные стерилизованные силизы (НА). Результаты показывают, что высокоурожайное производство лактической кислоты и уксусной кислоты (p) < 0.05), лучшая аэробная стабильность и высокая плотность Лактипланта

Phosphodiesterase type 5 and cancers: progress and challenges.

Cancers are an extraordinarily heterogeneous collection of diseases with distinct genetic profiles and biological features that directly influence response patterns to various treatment strategies as well as clinical outcomes. Nevertheless, our growing understanding of cancer cell biology and tumor progression is gradually leading towards rational, tailored medical treatments designed to destroy cancer cells by exploiting the unique cellular pathways that distinguish them from normal healthy counterparts. Recently, inhibition of the activity of phosphodiesterase type 5 (PDE5) is emerging as a

Hemostasis at the edge between physiology and cancer.

Hemostasis lies at the edge between physiology and cancer, where the coagulation cascade-initiated by tissue factor, thrombin generation, and fibrin deposition-shifts from vascular repair to tumor promotion. The interplay between coagulation and cancer is now recognized as a two-way street, with tumor cells activating the clotting system and coagulation components feeding back to promote malignancy. Tumor cells not only foster proliferation and invasion by overexpressing tissue factor and activating Protease-Activated Receptors (PAR1/PAR2) signalling, but they also induce endothelial cells and

Совпадение в полном тексте источника
… Gomez-Rosas P Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancer J Thromb Haemost 2025 23 6 1908 1919 10.1016/j.jtha.2025.02.029 40056983 Gomez-Rosas P et al (2025) Activated factor … XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancer. …

Полифенолы и нейродегенеративные заболевания: понимание знаний, механистические свидетельства и новые виды применения в области питания.

Полифенолы представляют собой разнообразную группу биоактивных веществ растительного происхождения, которые были исследованы в качестве многоцелевых возможностей для потенциальной профилактики и лечения нейродегенеративных заболеваний (НДИ). Мы провели комплексный библиометрический и механистический обзор, охватывающий 12 классов полифенола и семь основных НИЗ, с использованием записей из PubMed, Embase, Cochrane Bibrary и Web of Science (1940-2024). Для картирования исследовательских ландшафтов и новых тем использовались ключевые слова, анализы по группам и модели BERTopic. Механистические до

Все ли факторы риска равны в множестве миеломы?

Данные отсутствуют.

The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review.

Multiple myeloma (MM) is an incurable blood cancer that primarily affects older adults. Several frailty tools have been developed to address the heterogeneity of aging in this population. Uptake of these measures has been variable, leading to a gap in knowledge regarding the proportion of enrolled trial participants considered frail and uncertainty in the treatment-related effects and outcomes among this high-risk population. We performed a systematic review of therapeutic interventional MM clinical trials reporting on frailty. We included 43 clinical trials (24 randomized controlled trials an

Practice variations in indication, timing and outcome of Multiple Myeloma patients undergoing surgery for vertebral lesions - results from the European M2Spine study group.

PURPOSE: Painful vertebral lesions are pathognomonic in Multiple Myeloma (MM). While non-surgical management is generally preferred, some patients ultimately require surgical intervention. Here we describe the largest European cohort of MM patients with vertebral lesions to examine the practice variations of spine surgery in means of indication, timing and outcome. METHODS: This study included patients with MM vertebral lesions enrolled in the European M2Spine Registry (DRKS00033326) at seven European academic spine centers between 2005 and 2023. Retrospective analysis evaluated epidemiologic